Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Fischer

Showing results (301-310 of 323) with videos related to

Pageof 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2026
Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination TherapyJingwei Chen, Christopher Nelson, Matthew Wong, et al.
Science Translational Medicine|November 6, 2015
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastomaDaniel R Carter, Jayne Murray, Belamy B Cheung, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaLucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2020
Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination TherapyJingwei Chen, Christopher Nelson, Matthew Wong, et al.
Molecular Cell|August 15, 2025
PRDX6 contributes to selenocysteine metabolism and ferroptosis resistanceZhiyi Chen, Alex Inague, Kamini Kaushal, et al.
Science Advances|July 20, 2022
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibitionCarolina Nunes, Lisa Depestel, Liselot Mus, et al.
Molecular Cell|November 15, 2024
PRDX6 contributes to selenocysteine metabolism and ferroptosis resistanceZhiyi Chen, Alex Inague, Kamini Kaushal, et al.
Science (New York, N.Y.)|December 8, 2018
A mechanistic classification of clinical phenotypes in neuroblastomaSandra Ackermann, Maria Cartolano, Barbara Hero, et al.
Biorxiv : the Preprint Server for Biology|May 5, 2025
Oncogene Silencing via ecDNA MicronucleationLotte Brückner, Robin Xu, Jun Tang, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 7, 2012
Diagnostics of autoimmune bullous diseases in German dermatology departmentsNina van Beek, Diana Knuth-Rehr, Peter Altmeyer, et al.
Pageof 33

Showing results (301-310 of 323) with videos related to

Sort By:
Pageof 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2026
Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination TherapyJingwei Chen, Christopher Nelson, Matthew Wong, et al.
Science Translational Medicine|November 6, 2015
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastomaDaniel R Carter, Jayne Murray, Belamy B Cheung, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaLucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2020
Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination TherapyJingwei Chen, Christopher Nelson, Matthew Wong, et al.
Molecular Cell|August 15, 2025
PRDX6 contributes to selenocysteine metabolism and ferroptosis resistanceZhiyi Chen, Alex Inague, Kamini Kaushal, et al.
Science Advances|July 20, 2022
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibitionCarolina Nunes, Lisa Depestel, Liselot Mus, et al.
Molecular Cell|November 15, 2024
PRDX6 contributes to selenocysteine metabolism and ferroptosis resistanceZhiyi Chen, Alex Inague, Kamini Kaushal, et al.
Science (New York, N.Y.)|December 8, 2018
A mechanistic classification of clinical phenotypes in neuroblastomaSandra Ackermann, Maria Cartolano, Barbara Hero, et al.
Biorxiv : the Preprint Server for Biology|May 5, 2025
Oncogene Silencing via ecDNA MicronucleationLotte Brückner, Robin Xu, Jun Tang, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 7, 2012
Diagnostics of autoimmune bullous diseases in German dermatology departmentsNina van Beek, Diana Knuth-Rehr, Peter Altmeyer, et al.
Pageof 33